Document is current
Any future updates will be listed below
-
Authors
Mancina, Rosellina M. https://orcid.org/0000-0002-1126-3071
Valenti, Luca https://orcid.org/0000-0001-8909-0345
Romeo, Stefano https://orcid.org/0000-0001-9168-4898
- License Information
-
More Information
Article History
Received: 4 September 2024
Accepted: 15 September 2025
First Online: 17 October 2025
Competing interests
: S.R. received the research grant from AstraZeneca for basic-science research on steatotic liver disease and has been consulting for AstraZeneca, GSK, Celgene Corporation, Ribo-cure AB¸ Ultragenyx, Amgen, Sanofi, Wave Life Sciences, Novartis, Chiesi and Pfizer in the past 5 years; declares equity in Heptabio; and is an inventor on a patent titled “Method for treating fatty liver disease”, on PSD3, US application number 17,480266 filed on 21 September 2021. L.V. has been consulting for Novo Nordisk, Pfizer, Boehringer Ingelheim, Resalis, MSD and speaker for Viatris, Novo Nordisk, GSK. R.M.M. has nothing to declare.
